Zhao, Lin http://orcid.org/0000-0002-1678-7763
Koseki, Sabrina R. T.
Silverstein, Rachel A.
Amrani, Nadia
Peng, Christina http://orcid.org/0000-0001-7471-9059
Kramme, Christian
Savic, Natasha
Pacesa, Martin http://orcid.org/0000-0003-1560-5769
Rodríguez, Tomás C. http://orcid.org/0000-0002-8724-5427
Stan, Teodora http://orcid.org/0000-0002-0403-2080
Tysinger, Emma http://orcid.org/0000-0002-3958-8097
Hong, Lauren http://orcid.org/0000-0002-1675-4806
Yudistyra, Vivian http://orcid.org/0000-0001-8583-9232
Ponnapati, Manvitha R.
Jacobson, Joseph M.
Church, George M.
Jakimo, Noah
Truant, Ray http://orcid.org/0000-0003-2542-6641
Jinek, Martin http://orcid.org/0000-0002-7601-210X
Kleinstiver, Benjamin P. http://orcid.org/0000-0002-5469-0655
Sontheimer, Erik J. http://orcid.org/0000-0002-0881-0310
Chatterjee, Pranam http://orcid.org/0000-0003-3957-8478
Article History
Received: 24 February 2023
Accepted: 21 September 2023
First Online: 4 October 2023
Competing interests
: P.C. and J.M.J. are listed as inventors for US Patent Application 17/841,639 entitled: “Applications of Recombined ScCas9 Enzymes for PAM-free DNA Modification.” B.P.K is an inventor on patents and/or patent applications filed by Mass General Brigham that describe genome engineering technologies. B.P.K. is a consultant for EcoR1 capital, and is a scientific advisor to Acrigen Biosciences, Life Edit Therapeutics, and Prime Medicine. B.P.K. has a financial interest in Prime Medicine, Inc., a company developing therapeutic CRISPR-Cas technologies for gene editing. B.P.K.‘s interests were reviewed and are managed by MGH and MGB in accordance with their conflict-of-interest policies. The remaining authors declare no competing interests.